Cargando…
Treatment Advances in Sepsis and Septic Shock: Modulating Pro- and Anti-Inflammatory Mechanisms
Sepsis is currently defined as a life-threatening organ dysfunction caused by a dysregulated host response to infection, and it affects over 25 million people every year. Even more severe, septic shock is a subset of sepsis defined by persistent hypotension, and hospital mortality rates are higher t...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10142733/ https://www.ncbi.nlm.nih.gov/pubmed/37109229 http://dx.doi.org/10.3390/jcm12082892 |
_version_ | 1785033684118667264 |
---|---|
author | Marques, Adriana Torre, Carla Pinto, Rui Sepodes, Bruno Rocha, João |
author_facet | Marques, Adriana Torre, Carla Pinto, Rui Sepodes, Bruno Rocha, João |
author_sort | Marques, Adriana |
collection | PubMed |
description | Sepsis is currently defined as a life-threatening organ dysfunction caused by a dysregulated host response to infection, and it affects over 25 million people every year. Even more severe, septic shock is a subset of sepsis defined by persistent hypotension, and hospital mortality rates are higher than 40%. Although early sepsis mortality has greatly improved in the past few years, sepsis patients who survive the hyperinflammation and subsequent organ damage often die from long-term complications, such as secondary infection, and despite decades of clinical trials targeting this stage of the disease, currently, no sepsis-specific therapies exist. As new pathophysiological mechanisms have been uncovered, immunostimulatory therapy has emerged as a promising path forward. Highly investigated treatment strategies include cytokines and growth factors, immune checkpoint inhibitors, and even cellular therapies. There is much to be learned from related illnesses, and immunotherapy trials in oncology, as well as the recent COVID-19 pandemic, have greatly informed sepsis research. Although the journey ahead is a long one, the stratification of patients according to their immune status and the employment of combination therapies represent a hopeful way forward. |
format | Online Article Text |
id | pubmed-10142733 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-101427332023-04-29 Treatment Advances in Sepsis and Septic Shock: Modulating Pro- and Anti-Inflammatory Mechanisms Marques, Adriana Torre, Carla Pinto, Rui Sepodes, Bruno Rocha, João J Clin Med Review Sepsis is currently defined as a life-threatening organ dysfunction caused by a dysregulated host response to infection, and it affects over 25 million people every year. Even more severe, septic shock is a subset of sepsis defined by persistent hypotension, and hospital mortality rates are higher than 40%. Although early sepsis mortality has greatly improved in the past few years, sepsis patients who survive the hyperinflammation and subsequent organ damage often die from long-term complications, such as secondary infection, and despite decades of clinical trials targeting this stage of the disease, currently, no sepsis-specific therapies exist. As new pathophysiological mechanisms have been uncovered, immunostimulatory therapy has emerged as a promising path forward. Highly investigated treatment strategies include cytokines and growth factors, immune checkpoint inhibitors, and even cellular therapies. There is much to be learned from related illnesses, and immunotherapy trials in oncology, as well as the recent COVID-19 pandemic, have greatly informed sepsis research. Although the journey ahead is a long one, the stratification of patients according to their immune status and the employment of combination therapies represent a hopeful way forward. MDPI 2023-04-15 /pmc/articles/PMC10142733/ /pubmed/37109229 http://dx.doi.org/10.3390/jcm12082892 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Marques, Adriana Torre, Carla Pinto, Rui Sepodes, Bruno Rocha, João Treatment Advances in Sepsis and Septic Shock: Modulating Pro- and Anti-Inflammatory Mechanisms |
title | Treatment Advances in Sepsis and Septic Shock: Modulating Pro- and Anti-Inflammatory Mechanisms |
title_full | Treatment Advances in Sepsis and Septic Shock: Modulating Pro- and Anti-Inflammatory Mechanisms |
title_fullStr | Treatment Advances in Sepsis and Septic Shock: Modulating Pro- and Anti-Inflammatory Mechanisms |
title_full_unstemmed | Treatment Advances in Sepsis and Septic Shock: Modulating Pro- and Anti-Inflammatory Mechanisms |
title_short | Treatment Advances in Sepsis and Septic Shock: Modulating Pro- and Anti-Inflammatory Mechanisms |
title_sort | treatment advances in sepsis and septic shock: modulating pro- and anti-inflammatory mechanisms |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10142733/ https://www.ncbi.nlm.nih.gov/pubmed/37109229 http://dx.doi.org/10.3390/jcm12082892 |
work_keys_str_mv | AT marquesadriana treatmentadvancesinsepsisandsepticshockmodulatingproandantiinflammatorymechanisms AT torrecarla treatmentadvancesinsepsisandsepticshockmodulatingproandantiinflammatorymechanisms AT pintorui treatmentadvancesinsepsisandsepticshockmodulatingproandantiinflammatorymechanisms AT sepodesbruno treatmentadvancesinsepsisandsepticshockmodulatingproandantiinflammatorymechanisms AT rochajoao treatmentadvancesinsepsisandsepticshockmodulatingproandantiinflammatorymechanisms |